A phase 1b, open-label, multi-center, dose-escalation study of the safety, pharmacokinetics and therapeutic activity of cergutuzumab amunaleukin, an immunocytokine, which consists of a variant of interleukin-2 (IL2v) targeting carcinoembryonic antigen (CEA), and atezolizumab, an antibody that targets programmed death ligand 1 (anti-PDL1) administered intravenously, in patients with locally advanced and/or metastatic solid tumors

Authors
Category Primary study
Registry of TrialsOverview of Medical Research in the Netherlands
Year 2018
This article has no abstract
Epistemonikos ID: 4e8223bb855e5c10d8ebcbc9f48fde61bc1161bc
First added on: Apr 11, 2025